IL24 and head and neck squamous cell carcinoma: mda-7/IL-24 promotes both direct antitumor activity by inducing cancer-specific apoptosis as well as indirect antitumor activity by provoking anti-angiogenesis activity [12,13,14,15], in vitro and in vivo in preclinical animal models and in a Phase I clinical trial in patients with advanced cancers (includes breast carcinoma, colon carcinoma, squamous cell carcinoma of the head and neck, melanoma, large cell lymphoma, adrenal carcinoma, transitional cell carcinoma).